• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cancer Patients Believe Trials Are Moving Far Too Slowly, Survey Finds

Cancer Patients Believe Trials Are Moving Far Too Slowly, Survey Finds

September 6, 2021

The unprecedented haste with which COVID-19 vaccines were developed has had a big impact on cancer patients and their outlook on the speed (or lack thereof) of cancer trials.

Two-thirds of 1,110 cancer patient respondents to a recent survey indicated that they believe the current pace of cancer trials is far too slow; half of the respondents cited Operation Warp Speed’s successes as the reason for that belief.

Industry should continue to increase the use of real-world data and real-world evidence in order to accelerate drug development and improve diversity in trials, recommended COTA Healthcare, which sponsored the survey conducted by PureSpectrum. Additionally, the cross-industry collaborations sparked by the pandemic should be broadened to encompass other disease areas, like oncology, and innovative trial designs should be adopted to dismantle barriers to enrollment, the survey report recommended.

Many cancer patients and their families also are willing to share their own anonymous health data to speed up research. A substantial majority of those surveyed — 89 percent — were in favor of all oncology patients sharing their anonymous health data to support the research and discovery of cancer treatments.

Cancer patients are also eager to pitch in by contributing anonymous health data themselves, the survey found. Eighty-five percent of them said they would share their anonymous data if asked, while 87 percent said they wouldn’t mind if that data had already been shared if their personal information was taken out.

Further, a majority of respondents (86 percent) felt that oncologists should be actively discussing the value of sharing data with researchers through patient interactions, but less than half of them reported that their oncologist had brought up the subject.

“We must do more to support and cultivate patient interest in donating data, especially in traditionally underserved and underrepresented communities, to ensure we have enough rich, trustworthy, realistic data to develop safe and effective therapies,” the survey report said.

Read the full report here: https://bit.ly/2Yh1FJg.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing